Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
China
Anhui Provincial Hospital, Hefei, Anhui Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong He'nan Cancer Hospital, Zhengzhou, Henan Shandong Cancer Hospital, Jinan, Shandong Shanghai Chest Hospital, Shanghai, Shanghai Municipality Shanghai East Hospital, Shanghai, Shanghai Municipality Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality Sichuan Provincial Cancer Hospital, Chengdu, Sichuan Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang